Pivotal Therapeutics (PVTTF) 0.1200 $PVTTF
Pivotal Therapeutics Grants Incentive Stock Options
CNW Group - Mon Sep 15, 4:42PM CDT
Pivotal Therapeutics Inc. (OTCQX
VTTF; CSE VO), ("Pivotal" or the "Company"
, a specialty pharmaceutical company with a focus on Omega-3 therapies for cardiovascular disease and overall health, announced today that the Board of Directors approved the granting of stock options to an officer and an advisor at the close of business on Friday, September 12, 2014. Options to acquire a total of 1,000,000 common shares of the Company were granted in accordance with the provisions of the Company's 2011 stock option plan approved by shareholders on March 10, 2011. The options are exercisable at an exercise price of $0.20 and will expire five years following the date of grant.
Pivotal Announces Publication of a Clinical Trial Showing Beneficial Effects of VASCAZEN(R) In The Correction of Omega-3 Deficiency In Cardiovascular Patients
PR Newswire Europe - Wed Sep 10, 2:30PM CDT
WOODBRIDGE, Ontario, September 10, 2014 /PRNewswire/ --
Pivotal Announces Publication of a Clinical Trial Showing Beneficial Effects of VASCAZEN® In The Correction of Omega-3 Deficiency In Cardiovascular Patients
CNW Group - Wed Sep 10, 12:49PM CDT
Pivotal Therapeutics Inc. (OTCQX VTTF; CSE VO), ("Pivotal" or the "Company" , a specialty pharmaceutical company with a focus on Omega-3 therapies for cardiovascular disease ("CVD" and overall health, announced today the publication of results of a prospective randomized controlled trial in the U.S. that evaluated the effects of VASCAZEN(®) in the correction of Omega-3 deficiency in patients with one or more risk factors associated with CVD and evaluated VASCAZEN(®)'s concomitant effects on these risk factors including triglycerides, VLDL cholesterol, LDL cholesterol, and HDL cholesterol.
Pivotal Appoints Accomplished Healthcare and Investment Industry Veteran, Prakash Gowd, as Chief Financial Officer
CNW Group - Mon Sep 08, 10:50AM CDT
Pivotal Therapeutics Inc. (OTCQX VTTF; CSE VO), ("Pivotal" or the "Company" , a specialty pharmaceutical company with a focus on Omega-3 therapies for cardiovascular disease ("CVD" and overall health, today announced the appointment of Prakash Gowd as the Company's Chief Financial Officer. Mr. Gowd succeeds Eugene Bortoluzzi, who will remain Pivotal's Chief Executive Officer.
Unique Vasoprotective and Antihypertensive Effects of VASCAZEN(R)'s Formulation Presented at ESC Congress 2014
PR Newswire Europe - Wed Sep 03, 2:01PM CDT
WOODBRIDGE, Ontario, September 3, 2014 /PRNewswire/ --
Unique Vasoprotective and Antihypertensive Effects of VASCAZEN®'s Formulation Presented at ESC Congress 2014
CNW Group - Wed Sep 03, 1:19PM CDT
Pivotal Therapeutics Inc. (OTCQX VTTF; CSE VO), ("Pivotal" or the "Company" , a specialty pharmaceutical company with a focus on Omega-3 therapies for cardiovascular disease ("CVD" and overall health, announced today that the cardio-protective effects of Pivotal's unique Omega-3 formulation commercialized as VASCAZEN(®) was presented at the 2014 Annual Scientific Meeting of the European Society of Cardiology ("ESC" Congress 2014 in Barcelona, Spain, by Rasul et al. from the Laboratory of Biophotonics and Pharmacology of the University of Strasbourg, France.
Pivotal Therapeutics Announces Second Quarter Financial Results
CNW Group - Wed Aug 27, 2:19PM CDT
Pivotal Therapeutics Inc. (OTCQX VTTF; CSE VO), ("Pivotal" or the "Company" , a specialty pharmaceutical company with a focus on Omega-3 therapies for cardiovascular disease (CVD) and overall health, announced its operational highlights and financial results for the three months ended June 30, 2014. All dollar amounts referenced herein are in Canadian dollars unless otherwise stated.
Scientific Data Supports Superiority of Pivotal's Unique Omega-3 Formulation
PR Newswire Europe - Tue Aug 19, 11:23AM CDT
WOODBRIDGE, Ontario, August 19, 2014 /PRNewswire/ --
Pivotal Therapeutics To Explore Potential Commercial Partnership Opportunities in China
CNW Group - Wed Aug 06, 11:11AM CDT
Pivotal Therapeutics Inc. (OTCQX VTTF; CSE VO), ("Pivotal" or the "Company" , a specialty pharmaceutical company with a focus on Omega-3 therapies for cardiovascular disease (CVD) and overall health, announced today that it has entered into a Memorandum of Understanding to create a Joint Venture Distribution Agreement with ACGT Corporation ("ACGT" and associates. A leader in Canada's DNA services industry with extensive ties to China, ACGT will identify and introduce Pivotal to potential partners for the commercialization of its products in China.
Pivotal Therapeutics grants incentive stock options
PR Newswire - Fri Mar 14, 4:40PM CDT
Pivotal Therapeutics Inc. (OTCQX: PVTTF) (CSE: PVO), a specialty pharmaceutical company with a focus on Omega-3 therapies for cardiovascular disease and overall health, announced today that it has granted previously reserved stock options to certain of its directors, officers, employees and consultants in recognition of their contributions made in 2012. Options to acquire a total of 4,075,000 common shares of the Company were granted in accordance with the provisions of the Company's 2011 stock option plan approved by shareholders on March 10, 2011. The options are exercisable at an exercise price of $0.20 and will expire five years following the date of grant.
Pivotal Therapeutics appoints pharmaceutical executive James Connolly to Board of Directors
CNW Group - Mon Mar 10, 8:40AM CDT
Pivotal Therapeutics Inc. (OTCQX: PVTTF) (CSE: PVO), a specialty pharmaceutical company with a focus on Omega-3 therapies for cardiovascular disease (CVD) and overall health, announced today that James Connolly has been appointed to the Company's Board of Directors, effective immediately. Mr. Connolly brings over 27 years of experience in the pharmaceutical industry to Pivotal, including 23 years in various leadership positions at Wyeth, formerly American Home Products, a $23 billion pharmaceutical and health products company that was acquired by Pfizer in 2009.
Pivotal Therapeutics Grants Incentive Stock Options
CNW Group - Mon Sep 15, 4:42PM CDT
Pivotal Therapeutics Inc. (OTCQX
VTTF; CSE VO), ("Pivotal" or the "Company" , a specialty pharmaceutical company with a focus on Omega-3 therapies for cardiovascular disease and overall health, announced today that the Board of Directors approved the granting of stock options to an officer and an advisor at the close of business on Friday, September 12, 2014. Options to acquire a total of 1,000,000 common shares of the Company were granted in accordance with the provisions of the Company's 2011 stock option plan approved by shareholders on March 10, 2011. The options are exercisable at an exercise price of $0.20 and will expire five years following the date of grant. Pivotal Announces Publication of a Clinical Trial Showing Beneficial Effects of VASCAZEN(R) In The Correction of Omega-3 Deficiency In Cardiovascular Patients
PR Newswire Europe - Wed Sep 10, 2:30PM CDT
WOODBRIDGE, Ontario, September 10, 2014 /PRNewswire/ --
Pivotal Announces Publication of a Clinical Trial Showing Beneficial Effects of VASCAZEN® In The Correction of Omega-3 Deficiency In Cardiovascular Patients
CNW Group - Wed Sep 10, 12:49PM CDT
Pivotal Therapeutics Inc. (OTCQX
VTTF; CSE VO), ("Pivotal" or the "Company" , a specialty pharmaceutical company with a focus on Omega-3 therapies for cardiovascular disease ("CVD" and overall health, announced today the publication of results of a prospective randomized controlled trial in the U.S. that evaluated the effects of VASCAZEN(®) in the correction of Omega-3 deficiency in patients with one or more risk factors associated with CVD and evaluated VASCAZEN(®)'s concomitant effects on these risk factors including triglycerides, VLDL cholesterol, LDL cholesterol, and HDL cholesterol. Pivotal Appoints Accomplished Healthcare and Investment Industry Veteran, Prakash Gowd, as Chief Financial Officer
CNW Group - Mon Sep 08, 10:50AM CDT
Pivotal Therapeutics Inc. (OTCQX
VTTF; CSE VO), ("Pivotal" or the "Company" , a specialty pharmaceutical company with a focus on Omega-3 therapies for cardiovascular disease ("CVD" and overall health, today announced the appointment of Prakash Gowd as the Company's Chief Financial Officer. Mr. Gowd succeeds Eugene Bortoluzzi, who will remain Pivotal's Chief Executive Officer. Unique Vasoprotective and Antihypertensive Effects of VASCAZEN(R)'s Formulation Presented at ESC Congress 2014
PR Newswire Europe - Wed Sep 03, 2:01PM CDT
WOODBRIDGE, Ontario, September 3, 2014 /PRNewswire/ --
Unique Vasoprotective and Antihypertensive Effects of VASCAZEN®'s Formulation Presented at ESC Congress 2014
CNW Group - Wed Sep 03, 1:19PM CDT
Pivotal Therapeutics Inc. (OTCQX
VTTF; CSE VO), ("Pivotal" or the "Company" , a specialty pharmaceutical company with a focus on Omega-3 therapies for cardiovascular disease ("CVD" and overall health, announced today that the cardio-protective effects of Pivotal's unique Omega-3 formulation commercialized as VASCAZEN(®) was presented at the 2014 Annual Scientific Meeting of the European Society of Cardiology ("ESC" Congress 2014 in Barcelona, Spain, by Rasul et al. from the Laboratory of Biophotonics and Pharmacology of the University of Strasbourg, France. Pivotal Therapeutics Announces Second Quarter Financial Results
CNW Group - Wed Aug 27, 2:19PM CDT
Pivotal Therapeutics Inc. (OTCQX
VTTF; CSE VO), ("Pivotal" or the "Company" , a specialty pharmaceutical company with a focus on Omega-3 therapies for cardiovascular disease (CVD) and overall health, announced its operational highlights and financial results for the three months ended June 30, 2014. All dollar amounts referenced herein are in Canadian dollars unless otherwise stated. Scientific Data Supports Superiority of Pivotal's Unique Omega-3 Formulation
PR Newswire Europe - Tue Aug 19, 11:23AM CDT
WOODBRIDGE, Ontario, August 19, 2014 /PRNewswire/ --
Pivotal Therapeutics To Explore Potential Commercial Partnership Opportunities in China
CNW Group - Wed Aug 06, 11:11AM CDT
Pivotal Therapeutics Inc. (OTCQX
VTTF; CSE VO), ("Pivotal" or the "Company" , a specialty pharmaceutical company with a focus on Omega-3 therapies for cardiovascular disease (CVD) and overall health, announced today that it has entered into a Memorandum of Understanding to create a Joint Venture Distribution Agreement with ACGT Corporation ("ACGT" and associates. A leader in Canada's DNA services industry with extensive ties to China, ACGT will identify and introduce Pivotal to potential partners for the commercialization of its products in China. Pivotal Therapeutics grants incentive stock options
PR Newswire - Fri Mar 14, 4:40PM CDT
Pivotal Therapeutics Inc. (OTCQX: PVTTF) (CSE: PVO), a specialty pharmaceutical company with a focus on Omega-3 therapies for cardiovascular disease and overall health, announced today that it has granted previously reserved stock options to certain of its directors, officers, employees and consultants in recognition of their contributions made in 2012. Options to acquire a total of 4,075,000 common shares of the Company were granted in accordance with the provisions of the Company's 2011 stock option plan approved by shareholders on March 10, 2011. The options are exercisable at an exercise price of $0.20 and will expire five years following the date of grant.
Pivotal Therapeutics appoints pharmaceutical executive James Connolly to Board of Directors
CNW Group - Mon Mar 10, 8:40AM CDT
Pivotal Therapeutics Inc. (OTCQX: PVTTF) (CSE: PVO), a specialty pharmaceutical company with a focus on Omega-3 therapies for cardiovascular disease (CVD) and overall health, announced today that James Connolly has been appointed to the Company's Board of Directors, effective immediately. Mr. Connolly brings over 27 years of experience in the pharmaceutical industry to Pivotal, including 23 years in various leadership positions at Wyeth, formerly American Home Products, a $23 billion pharmaceutical and health products company that was acquired by Pfizer in 2009.
